A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer. by Ursin, G et al.
A Pilot Study of Urinary Estrogen Metabolites
(16a-OHE1 and 2-OHE1) in Postmenopausal
Women with and without Breast Cancer
Giske Ursin,1 Stephanie London,112 Frank Z. Stanczyk,3
Elisabet Gentzschein,3 Annlia Paganini-Hill,l Ronald K. Ross,'
and Malcolm C. Pike1
'Department of Preventive Medicine, University ofSouthern
California/Norris Comprehensive Cancer Center, Los Angeles, California;
2National Institute of Environmental Health Sciences, Research Triangle
Park, North Carolina; 3Department of Obstetrics and Gynecology,
University of Southern California/Los Angeles County Women's Hospital,
Los Angeles, California
The two main pathways for metabolizing estrogen are via 16a-hydroxylation and 2-hydroxylation.
The 16a-hydroxy metabolites are biologically active; the 2-hydroxy metabolites are not. It is
suggested that women who metabolize a larger proportion of their endogenous estrogen via the
16a-hydroxy pathway may be at significantly elevated risk of breast cancer compared with
women who metabolize proportionally more estrogen via the 2-hydroxy pathway. In particular, it
is suggested that the ratio of urinary 2-hydroxyestrone (2-OHEl) to 16a-hydroxyestrone
(16a-OHE1) is an index of reduced breast cancer risk. This pilot study compared this ratio in
postmenopausal women diagnosed with breast cancer to those of healthy controls. Urinary
concentrations of estrone (El), 17,Bestradiol (E2) and estriol (E3) were also quantified. White
women who were subjects in a previous breast cancer case-control study at our institution were
eligible for inclusion. All participants provided a sample of their first morning urine. The results
from the first 25 cases and 23 controls are presented here. The ratio of2-OHE, to 16a-OHE1 was
12% lower in the cases (p=0.58). However, urinary El was 30% higher (p=0.10), E2 was 58%
higher (p=0.07), E3 was 15% higher (p=0.48), and the sum of El, E2, and E3 was 22% higher
(p=0.16) in the cases. These preliminary results do not support the hypothesis that the ratio of
the two hydroxylation metabolites (2-OHE1/16a-OHE1) is an important risk factor for breast
cancer or that it is a better predictor of breast cancer risk than levels of E1, E2 and E3 measured in
urine. - Environ Health Perspect 105(Suppl 3):601-605 (1997)
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Introduction
Overwhelming evidence supports a role of part, and possiblycompletely, the decreased
ovarian hormones in the etiology ofbreast breast cancer risk associated with early
cancer (1). At menopause circulating estro- menopause (2). In postmenopausal women,
gens decline sharply, explaining in large the major source ofestrogen arises from the
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peripheral conversion ofandrostenedione
in adipose tissue (3). This, together with
decreased sex hormone-binding globulin
levels, is the most probable explanation for
the higher breast cancer risk in obese post-
menopausal women (4). Both elevated
serum estrogen levels (5-16) and increased
urinary excretion rates ofestrone (El),
17,B-estradiol (E2) and estriol (E3) have been
found in breast cancer cases as compared
with controls (17-24).
The two main pathways for metabo-
lizing estrogen are via 16a-hydroxylation
and 2-hydroxylation, and the major estro-
gen metabolites excreted in urine are 2-
hydroxy products [2-hydroxyestrone
(2-OHE1), 2-hydroxyestradiol (2-OH-E2),
2-methoxyestrone (2-MeO-El)], nonme-
tabolized El, 16a-hydroxy products [E3,
16a-hydroxyestrone (16a-OHE,)]and E2
(25). The 16a-metabolites are biologically
active (26,27); the 2-hydroxy metabolites
are not (28).
The extent towhich estrogen is metabo-
lized via the 16a-hydroxylation pathway
may be associated with breast cancer risk
(29-31). Increased 16a-hydroxylation
activity, but not 2-hydroxylation activity,
has been observed in mice strains with high
spontaneous mammary tumor formation
(29). In humans, the extent ofbiotransfor-
mation of3H-E2 via the 16a-hydroxylation
pathway was 4.6-fold higher in terminal
duct lobular units in breast tissue from
breast cancer cases than in breast tissue
from reduction mammoplasty controls
(32). Two other epidemiologic studies sug-
gested that the extent of 16a-hydroxylation
was higher in women with breast cancer
(33) and in women with high familial risk
of breast cancer (34) than in controls.
However, a third study found no elevation
of 16a-hydroxylation in breast cancer cases
comparedwith controls (25).
We selected women interviewed in a
previous population-based epidemiologic
studyto determinewhetherpostmenopausal
womenwith breast cancerhave a lower ratio
of urinary 2-OHE1 to 16cx-OHE1 than
controls. We report here the data from the
first 25 cases and 23 controls.
Methods
This study was approved by the local
Institutional Review Board. Written
informed consent was obtained from
each participant.
Eligible cases were identified from
women between 55 and 64 years ofage
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diagnosed with histologically confirmed
breast cancer, identified through the
Los Angeles County Cancer Surveillance
Program (a National Cancer Institute
Surveillance, Epidemiology, and End
Results Program Registry), who had partici-
pated in a previous breast cancer case-con-
trol study conducted at our institution (35).
The dates ofdiagnosis were 1 March 1987
through 31 December 1989. Only women
diagnosed with incident cancer at stage II or
less [tumor size <T2, nodes <N1, and no
distant metastasis (Mo), or T3, No, Mo]
were included (36). Eligible controls were
participants in the same case-control study
who had not been diagnosed with breast
cancer. Subjects had to be English-speaking
whites (including Hispanics), and residents
ofLosAngeles County.
Cases and controls were contacted; the
most recent interviewees were contacted
first. Eligibility was determined based on a
phone interview. Subjects who had used
medications during the previous 6 months
that may have interfered with estrogen
metabolism (specifically, cimetidine, thy-
roxine, estrogen, progesterone, tamoxifen,
or 023 fatty acid supplements) (37-40)
were eliminated from the study. Subjects
who had general anesthesia in the previous
3 months or weighed more than 200 lb
(90 kg) were also excluded.
A box containing a 100-ml urine vial
with a 100-mg ascorbate tablet, a small
cooler with an ice pack, an informed con-
sent form, and a questionnaire on recent
intake ofmedication, alcohol, and specific
foods was shipped to each eligible woman
who agreed to participate. First morning
urine samples were collected, aliquoted, and
frozen at -70°C within 6 hr after specimens
were produced.
Urine samples were sent to two differ-
ent laboratories. Batches of30 samples (15
from cases, 15 from controls, including
10% duplicates) were coded and shipped
on dry ice. The only identifiers on the sam-
ples were code numbers ensuring that the
laboratories were blinded as to case or con-
trol status ofthe individual samples and to
the identity ofduplicates.
EnzymeImmunoassayof
16a-OHE1 and2-OHE,
Measurements of urinary 16a-OHE1 and
2-OHE1 were carried out using commer-
ciallyavailable competitive enzyme immuno-
assay (EIA) kits (Estramet, Immuna Care
Corporation, Bethlehem, PA) to measure
2-OHE, and 16a-OHE1 directly in urine.
The two metabolites were measured
simultaneously to avoid interassay varia-
tion. This method has been described in
detail by Klug et al. (41). In brief, mono-
clonal antibodies to the estrogen metabo-
lites were immobilized directly to the solid
phase, and the metabolite standards were
conjugated to alkaline phosphatase enzyme.
Each urine sample was acidified and sub-
jected to 13-glucuronidase/aryl sulfatase
hydrolysis before assay.
The 16ct-OHE, and 2-OHE1 EIA kits
were validated by comparing values
obtained with these kits to values obtained
by gas chromatography-mass spectroscopy
(41). The inter- and intraassay coefficients
ofvariation for 2-OHE1 and 166a-OHE,
were between 7 and 13% (41). Creatinine
values above 0.20 mg/ml are considered
necessary to obtain adequate reproducibil-
ity of the 2-OHE, and 16ac-OHE, assays
(HL Bradlow, personal communication).
Radioimmunoassay of
UrinaryE1, E2, andE3
Measurements of urinary E1, E2, and E3
were carried out using high-performance
liquid chromatography-radioimmunoassay
(HPLC-RIA). Each urine sample was acid-
ified and subjected to P-glucuronidase/aryl
sulfatase hydrolysis before assay.
Following the addition ofapproximately
1000 dpm of 3H-E1, 3H-E2, and 3H-E3,
which served as internal standards to follow
procedural losses, solid phase extraction was
performed. Ethyl acetate was used to extract
the estrogens, the organic solvent was evapo-
rated and the extract was subjected to
HPLC. A reverse-phase HPLC column
(C18; 5p) was used to elute E3, E2, andEl in
a gradient ofacetonitrile:water:acetic acid
(40:60:0.1) at a flow rate of 1 ml/min. The
retention times for E3, E2, and E1 were 4,
13, and 16 min, respectively.
The E1, E2, and E3 fractions were
quantified by RIA, using methods previ-
ously described by Katagiri et al. (42),
Stanczyk et al. (43), and Cassidenti et al.
(44). Appropriate quality controls were
used with each set of samples that was
assayed to monitor assay reliability.
StatisticalAnalysis
All directly measured hormone variables
were lognormally distributed, and the sta-
tistical significance of the difference in
these variables between cases and controls
was evaluated using t tests of the natural
logs of these values. The statistical sig-
nificance of the differences in 2-OHE1/
16a-OHE, between cases and controls
was evaluated using Wilcoxon's nonpara-
metric rank sum test. Statistical analyses
were conducted using SAS (SAS Institute,
Cary, NC).
Results
The full study will include almost 100
cases and 100 controls. We reported here
results from the first subset ofthe women
enrolled in the study.
The results for the first two batches of
urine samples were available for the analy-
ses reported here. These represented 27
cases, 27 controls, and 6 duplicate samples.
We excluded six samples with low creati-
nine values. Among the remaining 25 cases
and 23 controls, the mean 16x-OHE, was
8.0% higher and the mean 2-OHE1 was
3.9% lower in cases than in controls (Table
1). The ratio of 2-OHE1 to 16a-OHE,
was 12.0% lower in cases. None of these
differences were statistically significant.
The individual values of 2-OHEl/16x-
OHE, are plotted in Figure 1.
Ratios of 2-OHE1/166a-OHE1 below
2.0 have been suggested as an index ofhigh
risk ofbreast cancer (HL Bradlow, personal
communication). However, in this study,
nearly all cases and controls had at least
this low ratio; 20 of23 controls and 24 of
25 cases had ratios less than 2.0.
El was 30% higher (p=0.10) and E2
was 58% higher (p=0.07) in cases than in
controls. E3 was 15% higher and the sum
ofE1, E2, and E3 was 22% higher in cases;
neither result was statistically significant.
Table 1. Mean levels of estrogen metabolites in postmenopausal breast cancer cases and controls.
Urinary
metabolitea
2-OHE,
166a-OHE,
2-OHE1/16a-OHE,
El
Cases, n= 25
Mean SE
7.09 0.89
5.27 0.47
1.39 0.10
3.14 0.34
Controls, n= 23
Mean SE
7.38 0.77
4.88 0.37
1.58 0.20
2.42 0.34
E2 0.87 0.14 0.55 (
E3 5.63 0.66 4.90 c
E1+E2+E3 9.64 0.94 7.87 c
Ong/(mg creatinine). b[jicases mean value)/(controls mean value)] x 100.
Difference,b %
-3.9
8.0
-12
30
58
15
22
0.06
0.49
0.81
pvalue
0.89
0.61
0.58
0.10
0.07
0.48
0.16
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Figure 1. Urinary 2-OHE/16a-OHE, in 25 postmenopausal breast cancer cases (s) and 23 controls (+).
The coefficients ofvariation for the six
blind duplicates were 13% for 2-OHEl,
20% for 16a-OHEI, 13% for El, 14% for
E2, and 24% for E3.
Discussion
Our results confirm previous studies that
El and E2 are higher in urine ofpostmeno-
pausal breast cancer cases than controls
(17-24). However, we found only small
differences between cases and controls in
urinary levels of16a-OHEI, 2-OHEI, and
the ratio ofthe two.
The epidemiologic data addressing
the 2-OHEI/16a-OHE1 hypothesis are
sparse. Schneider and co-workers used a
radiometric method to determine the
extent of 2- and 16a-hydroxylation (33).
They injected 33 peri- and postmenopausal
breast cancer patients and 10 postmeno-
pausal controls with E2 tracers labeled with
3H in the 17a, C-2, and 16a position.
They drew serial blood samples before
and after isotope administration and
determined the rate and extent of the
oxidative metabolism at positions 17a,
C-2, and 16a. Cases had 60% higher
extent of 16a-hydroxylation than controls;
this difference was statistically significant.
However, the two groups did not differ
significantly in the extent of2-hydroxyla-
tion, which was only 5% higher among
cases. The ratio of the average level of
16a-hydroxylation to the average level of
2-hydroxylation was 52% greater in the
breast cancer cases than in the controls.
No data on total estrogen values were
provided.
The only other published study of
16a-/2-hydroxylation in breast cancer
patients was performed by Adlercreutz et
al. (25). They examined estrogen metabo-
lites in young Finnish premenopausal
breast cancer cases (n= 10) and control
women on an omnivorous normal Finnish
diet (n = 12) or on a lacto-vegetarian diet
(n= 11). There was no statistically signi-
ficant difference in 2-OHE1, 16a-OHEI,
or total urinary estrogens (E1, E2, E3,
2-OHE1, 16a-OHE1, and eight other
estrogen metabolites) between breast
cancer patients and omnivores or breast
cancer patients and lacto-vegetarians.
Both of the above-mentioned studies
measured metabolites after breast cancer
diagnosis. In an attempt to determine
whether an elevated ratio of 16ax- to
2-hydroxylation precedes diagnosis,
Osborne and co-workers used radiometric
methods to study estrogen metabolism in
premenopausal women presumed to be at
high or low risk of breast cancer (34).
They found that women at high risk of
breast cancer (family history of breast
cancer or epithelial atypia in a previous
biopsy) had a significantly higher (22%)
extent of 166a-hydroxylation than women
without high-risk lesions or a family his-
tory (low-risk controls). High-risk women
had a similarly elevated extent of 16a-
hydroxylation of E2 as the breast cancer
patients in the study by Schneider et al.
(33). Translated to relative risks, the data
of Osborne et al. (34) suggest that one
standard deviation increase in the extent of
16a-hydroxylation from the level of
low-risk controls may result in a 3-fold
elevation of breast cancer risk. No data on
total estrogen values were provided.
Several factors could also have affected
our results. We studied a select group of
women with few extraneous factors that
might influence estrogen metabolism.
With this approach we excluded a large
number ofwomen. Based on the first 300
women identified, we excluded 55 to 60%
for a variety of reasons: 10% were above
200 lb, 15% were smokers, 25% of con-
trols were taking estrogen replacement
therapy, 10% were on other medications,
and at least 20% of the cases were on
tamoxifen. However, none ofthese exclu-
sions appear likely to introduce any biases
in any direction because they were applied
equally to cases and controls.
The intraassay coefficients ofvariation
for the assays used in this study were 13
and 20%, respectively. These values are
somewhat higher than the published
values of approximately 10% (41). It is,
however, unclear whether the original
reproducibility tests were conducted in
pre- or postmenopausal women. Ziegler
(45) addresses reproducibility problems
elsewhere in this volume. She found that
the reproducibility of this assay was low
when testing urines with low estrogen con-
centrations. As a result of these findings,
both the 2-OHE1 and 16ac-OHE, tests
are being adjusted to improve repro-
ducibility at low concentrations (HL
Bradlow, personal communication).
The evidence is rather clear that certain
diets influence the extent of 16a- and 2-
hydroxylation (46-49). Recent dietary
changes in cases-controls could obscure or
accentuate the differences between these
groups. We addressed this issue by asking
participants whether they have changed
their diet in the past 10 years, and we will
include acomplete analysis ofthese data in a
subsequent report on the completed study.
It is not known whether the onset of
cancer may affect 2- and 16a-hydroxyla-
tion. We are therefore conducting another
study examining the association between
the extent of 2- and 16a-hydroxylation
and familial risk ofbreast cancer in healthy
youngwomen.
In conclusion, our preliminary results
from this case-control study of breast
cancer in postmenopausal women do not
support the hypothesis that the ratio ofuri-
nary 2-OHE1 to 16a-OHE, is a better
predictor ofbreast cancer risk than urinary
E1, E2, and E3.
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